VRDN Viridian Therapeutics, Inc.\DE
Pharmaceutical Preparations · Nasdaq · SEC CIK 1590750 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-62.8%
TTM net income YoY-50.2%
TTM EPS YoY—
Revenue 3-yr CAGR323.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,781.4%
Net margin-1,724.1%
FCF margin-1,305.4%
EBITDA margin-1,778.7%
Returns
ROE-83.7%
ROA-56.5%
ROIC (approx.)-97.2%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets43.5%
Debt / equity0.00x
Current ratio14.46x
Interest coverage-19.27x
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-14.0%
Payout ratio—
Capex / revenue7.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $25.75M | $284,000 | $141,000 | $132,000 | $70.57M | $75,000 | $72,000 | $72,000 |
| Cost of revenue | $1.53M | — | — | — | $0 | — | — | — |
| Gross profit | $24.23M | — | — | — | $70.57M | — | — | — |
| R&D expense | $70.09M | $71.58M | $77.63M | $89.21M | $86.26M | $86.63M | $76.83M | $71.96M |
| SG&A expense | $57.61M | $54.98M | $38.68M | $33.67M | $24.32M | $20.22M | $17.10M | $15.58M |
| Operating income | -$103.48M | -$126.27M | -$116.17M | -$122.75M | -$40.01M | -$106.77M | -$93.87M | -$87.47M |
| Interest expense | $9.27M | $8.31M | $3.46M | $3.28M | $560,000 | $514,000 | $550,000 | $517,000 |
| Net income | -$101.21M | -$127.12M | -$104.90M | -$120.36M | -$34.60M | -$100.73M | -$86.91M | -$79.72M |
| EBITDA | -$103.13M | -$126.15M | -$116.05M | -$122.63M | -$39.90M | -$106.65M | -$93.75M | -$87.35M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Weighted avg. shares (diluted) | — | — | — | — | 81.78M | 81.59M | 81.34M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $172.86M | $164.99M | $176.35M | $212.38M | $169.65M | $117.32M | $116.22M | $99.59M |
| Short-term investments | $782.35M | $816.54M | $585.84M | $662.27M | $321.25M | $446.03M | $520.42M | $617.99M |
| Receivables | $29.78M | — | — | $0 | — | — | — | — |
| Inventory | $85,000 | — | — | $0 | — | — | — | — |
| Current assets | $1.01B | $1.08B | $784.74M | $894.23M | $571.91M | $578.75M | $657.24M | $738.46M |
| PP&E, net | $2.97M | $2.77M | $1.13M | $1.23M | $1.12M | $1.09M | $1.16M | $1.24M |
| Intangibles | $9.79M | $10.00M | — | $0 | — | — | — | — |
| Total assets | $1.03B | $1.10B | $789.02M | $899.42M | $577.14M | $582.32M | $660.98M | $742.40M |
| Current liabilities | $70.05M | $63.79M | $51.80M | $70.70M | $50.70M | $52.59M | $33.73M | $47.87M |
| Short-term debt | — | — | — | — | — | $8.44M | — | $0 |
| Long-term debt | — | — | — | — | $20.89M | $12.35M | $20.68M | $20.58M |
| Total debt | — | — | — | — | $20.89M | $20.79M | $20.68M | $20.58M |
| Total liabilities | $447.97M | $435.14M | $153.01M | $177.25M | $74.17M | $67.16M | $56.51M | $70.76M |
| Shareholders' equity | $580.70M | $662.10M | $636.01M | $722.17M | $502.97M | $515.17M | $604.47M | $671.64M |
| Net debt | — | — | — | — | -$148.76M | -$96.54M | -$95.53M | -$79.01M |
| Shares outstanding | 113.53M | 113.24M | 102.46M | 101.83M | 82.23M | 81.65M | 81.59M | 80.99M |
| Cash flow statement | ||||||||
| Operating cash flow | -$92.77M | -$105.32M | -$119.65M | -$23.75M | -$84.61M | -$75.37M | -$92.65M | -$73.33M |
| Capital expenditure | $370,000 | $1.31M | $23,000 | $240,000 | $127,000 | $42,000 | $86,000 | $114,000 |
| Free cash flow | -$93.14M | -$106.63M | -$119.68M | -$23.99M | -$84.74M | -$75.42M | -$92.74M | -$73.45M |
| Investing cash flow | $24.34M | -$231.16M | $77.26M | -$339.42M | $126.08M | $75.72M | $100.06M | -$62.91M |
| Financing cash flow | $77.61M | $325.12M | $6.36M | $405.91M | $10.86M | $764,000 | $9.21M | $35.52M |
| Depreciation & amortization | $343,000 | $117,000 | $121,000 | $120,000 | $110,000 | $113,000 | $117,000 | $123,000 |
| Stock-based compensation | $17.23M | $16.98M | $13.39M | $11.99M | $11.25M | $10.84M | $10.22M | $8.97M |
Free plan shows the latest 8 periods; Pro shows all 54 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.